At a glance
A spadin-related peptide investigated in potassium-channel biology.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes preclinical mood-related experiments. An antidepressant-like result in an animal test is not equivalent to demonstrated treatment of human depression.[3][4][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of PE-22-28.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (µg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 50 µg | 1.5 units (0.015 mL) |
| Weeks 3–4 | 100 µg | 3 units (0.03 mL) |
| Weeks 5–8 | 100 µg | 3 units (0.03 mL) |
| Weeks 9–12 (Optional) | 150 µg | 4.5 units (0.045 mL) |
| Weeks 13–16 (Optional) | 200 µg | 6 units (0.06 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses a practical 3.0 mL dilution for accurate measurement. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Many researchers find 100–150 µg sufficient given PE-22-28’s high potency[3].
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support rapid neuroplasticity, mood regulation, and neuroprotection through selective TREK-1 inhibition[1][3].
- Schedule: Daily subcutaneous injections for 12–16 weeks (8 weeks minimum).
- Dose Range: 50–200 µg daily with conservative titration; many find 100–150 µg adequate.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for precise low-volume measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; replace vials every 4 weeks.
Suggested conservative daily titration approach.
- Start: 50 µg daily for Weeks 1–2 to assess tolerance.
- Increase: 100 µg daily for Weeks 3–8 (standard maintenance dose).
- Optional Titration: 150 µg (Weeks 9–12) or 200 µg (Weeks 13–16) only if well-tolerated and additional effect desired.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 12–16 weeks; 8 weeks minimum.
- Timing: Consistent daily time; rotate injection sites systematically.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks for optimal potency.
- Allow vials to reach room temperature before opening to reduce condensation; protect from light.
- Replace with fresh vial every 4 weeks even if peptide remains; bacteriostatic water sterility is guaranteed for 28 days after first puncture[10].
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper and injection site with alcohol; allow both to air-dry completely[6][7].
- Pinch a skinfold of subcutaneous tissue; insert the needle at 45° (or 90° if using very short needles with ample subcutaneous fat)[6].
- Do not aspirate for subcutaneous injections; inject solution slowly and steadily[6].
- Rotate sites systematically (abdomen at least 2 inches from navel, front/outer thighs, outer upper arms) to prevent lipohypertrophy and maintain absorption consistency[7].
- Given the very small injection volumes (often ≤0.10 mL), technique precision is critical. Consider using 30- or 50-unit insulin syringes for doses under 10 units to improve measurement accuracy.
- Withdraw needle at the same angle inserted; apply gentle pressure if needed; dispose of syringe immediately in sharps container.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration. Replace vials every 4 weeks to maintain potency.
-
Peptide Vials (PE-22-28, 10 mg each):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 3 vials
- 16 weeks ≈ 4 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PLoS Biology (2010) — Mazella et al.: Spadin, a sortilin-derived peptide targeting TREK-1 channels; novel antidepressant mechanism (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
Neuropharmacology (2012) — Moha Ou Maati et al.: Spadin as antidepressant; absence of TREK-1-related side effects (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC — 4 Ways to Take Insulin; section on injection site rotation and subcutaneous technique (opens in a new tab)www.cdc.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.